

Miodrag Janic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/992484/publications.pdf>

Version: 2024-02-01

36
papers

565
citations

759055

12
h-index

642610

23
g-index

36
all docs

36
docs citations

36
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Arterial Stiffness and Cardiovascular Therapy. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	107
2	Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018, 17, 153.	2.7	70
3	Coenzyme Q10 Supplementation Decreases Statin-Related Mild-to-Moderate Muscle Symptoms: A Randomized Clinical Study. <i>Medical Science Monitor</i> , 2014, 20, 2183-2188.	0.5	48
4	Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males – a pilot study. <i>Atherosclerosis</i> , 2011, 215, 446-451.	0.4	37
5	The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial. <i>European Journal of Internal Medicine</i> , 2012, 23, 261-266.	1.0	36
6	Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1197.	1.8	31
7	Reduction of age-associated arterial wall changes by low-dose valsartan. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1243-1249.	0.8	19
8	Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. <i>Heart and Vessels</i> , 2013, 28, 246-254.	0.5	18
9	Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 420-425.	0.9	17
10	Associations among different functional and structural arterial wall properties and their relations to traditional cardiovascular risk factors in healthy subjects: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 29.	0.7	16
11	A Combination of Low-Dose Fluvastatin and Valsartan Decreases Inflammation and Oxidative Stress in Apparently Healthy Middle-Aged Males. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2014, 34, 208-212.	1.2	16
12	Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat “Aging-Related Disorders”. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1844.	1.8	16
13	A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts. <i>Medical Science Monitor</i> , 2012, 18, BR366-BR374.	0.5	13
14	Treatment With Low-dose Atorvastatin, Losartan, and Their Combination Increases Expression of Vasoactive-Related Genes in Rat Aortas. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 177-183.	1.0	12
15	A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	12
16	Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall. <i>Current Vascular Pharmacology</i> , 2018, 17, 6-15.	0.8	12
17	A new anti-ageing strategy focused on prevention of arterial ageing in the middle-aged population. <i>Medical Hypotheses</i> , 2013, 80, 837-840.	0.8	11
18	Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2796.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men. <i>Rejuvenation Research</i> , 2016, 19, 115-119.	0.9	9
20	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). <i>Diabetes Therapy</i> , 2022, 13, 795-810.	1.2	9
21	Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 181-186.	1.1	8
22	The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig. <i>European Journal of Pharmacology</i> , 2014, 743, 31-36.	1.7	7
23	The influence of May-Thurner syndrome on post-thrombotic syndrome in young women. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 393-398.	0.6	7
24	Long-term improvement of arterial wall characteristics in patients with diabetes mellitus type 1 using cyclic, intermittent treatment with a low-dose fluvastatin and valsartan combination. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1207-1211.	0.8	6
25	Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-9.	1.0	4
26	Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study. <i>Vascular Pharmacology</i> , 2017, 99, 45-52.	1.0	3
27	Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6648.	1.8	3
28	The "Rise"Peak"Fall"Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 68, 74-80.	0.8	2
29	1148-P: Antioxidative Effects of Empagliflozin and Metformin in Type 1 Diabetes Mellitus Patients. <i>Diabetes</i> , 2020, 69, 1148-P.	0.3	2
30	Problematika uÅ¼ivanja pijaÄz dodanim sladkorjem v Sloveniji in svetu. <i>ZdravniÅki Vestnik</i> , 2019, 87, .	0.1	2
31	Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study. <i>International Angiology</i> , 2018, 37, 356-364.	0.4	1
32	Zaviralci SGLT-2. <i>ZdravniÅki Vestnik</i> , 2018, 87, 493-506.	0.1	1
33	Obravnavanje bolnikov s sladkorno boleznijo v Åasu epidemije covida-19. <i>ZdravniÅki Vestnik</i> , 2021, 90, 322-335.	0.1	0
34	Metformin: od mehanizmov delovanja do napredne kliniÅne uporabe. <i>ZdravniÅki Vestnik</i> , 2017, 86, .	0.1	0
35	PrepreÄevanje venskih trombolizmov pri internistiÅnih bolnikih v bolniÅnici. <i>ZdravniÅki Vestnik</i> , 2018, 87, .	0.1	0
36	2198-PUB: The Impact of Basal Insulin Initiation to Background Sulfonylurea Treatment on Hypoglycemia Occurrence: Evaluation of the Balkan Cohort of Dune Study. <i>Diabetes</i> , 2020, 69, 2198-PUB.	0.3	0